Drug Profile

SIL 1002

Alternative Names: SIL-1002; SL-1002

Latest Information Update: 24 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Saol Therapeutics
Class Analgesics; Antispastics
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Muscle spasticity; Musculoskeletal pain

Most Recent Events

17 Apr 2025 Saol Therapeutics completes end of phase II meeting with USFDA
30 Oct 2024 Saol Therapeutics plans to meet with the US FDA in the first half of 2025 to determine the next steps for SL 1002
30 Oct 2024 Efficacy and adverse events data from a phase II clinical trials in Muscle spasticity released by Saol Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com